These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16004887)

  • 1. Triple-coated stents (Hirudin/Iloprost/Paclitaxel): an in vitro approach for characterizing the antiproliferative potential of each individual compound.
    Voisard R; Stemberger A; Baur R; Herter T; Hähnel I; Resch A; Seliger C; Hemmer W; Hannekum A; Hombach V; Alt E
    Int J Cardiol; 2005 Jul; 102(3):425-33. PubMed ID: 16004887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model.
    Salu KJ; Bosmans JM; Huang Y; Hendriks M; Verhoeven M; Levels A; Cooper S; De Scheerder IK; Vrints CJ; Bult H
    Cardiovasc Res; 2006 Feb; 69(2):536-44. PubMed ID: 16386237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local catheter-based delivery of antithrombotic or antiproliferative drugs: a new concept for prevention of restenosis.
    Herdeg C; Goehring-Frischholz K; Zuern C; Geisler T; Hartmann U; Hoevelborn T; Haase KK; Gawaz M
    Thromb Res; 2008; 123(2):236-43. PubMed ID: 18452977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of endothelial cells in vitro on Paclitaxel-loaded coronary stents.
    Prasad CK; Resmi KR; Krishnan LK; Vaishnav R
    J Biomater Appl; 2005 Apr; 19(4):271-86. PubMed ID: 15788425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis.
    Voisard R; Krebs R; Baur R; Hombach V
    Coron Artery Dis; 2010 Aug; 21(5):286-91. PubMed ID: 20508518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative stent coatings: Taxol and related compounds.
    Herdeg C; Oberhoff M; Karsch KR
    Semin Interv Cardiol; 1998; 3(3-4):197-9. PubMed ID: 10406693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model.
    Bhargava B; Reddy NK; Karthikeyan G; Raju R; Mishra S; Singh S; Waksman R; Virmani R; Somaraju B
    Catheter Cardiovasc Interv; 2006 May; 67(5):698-702. PubMed ID: 16575925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model.
    Yang W; Ge J; Liu H; Zhao K; Liu X; Qu X; Li W; Huang Y; Sun A; Zou Y
    Cardiovasc Res; 2006 Dec; 72(3):483-93. PubMed ID: 17020754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
    Krucoff MW; Kereiakes DJ; Petersen JL; Mehran R; Hasselblad V; Lansky AJ; Fitzgerald PJ; Garg J; Turco MA; Simonton CA; Verheye S; Dubois CL; Gammon R; Batchelor WB; O'Shaughnessy CD; Hermiller JB; Schofer J; Buchbinder M; Wijns W;
    J Am Coll Cardiol; 2008 Apr; 51(16):1543-52. PubMed ID: 18420096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of paclitaxel and nitric oxide as a novel treatment for the reduction of restenosis.
    Lin CE; Garvey DS; Janero DR; Letts LG; Marek P; Richardson SK; Serebryanik D; Shumway MJ; Tam SW; Trocha AM; Young DV
    J Med Chem; 2004 Apr; 47(9):2276-82. PubMed ID: 15084126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
    Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
    Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents.
    Muldowney JA; Stringham JR; Levy SE; Gleaves LA; Eren M; Piana RN; Vaughan DE
    Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):400-6. PubMed ID: 17158352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
    Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
    Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
    Grube E; Dawkins KD; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Buellesfeld L; Koglin J; Russell ME
    Eur Heart J; 2007 Nov; 28(21):2578-82. PubMed ID: 17938126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost.
    Alt E; Haehnel I; Beilharz C; Prietzel K; Preter D; Stemberger A; Fliedner T; Erhardt W; Schömig A
    Circulation; 2000 Mar; 101(12):1453-8. PubMed ID: 10736292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetramethylpyrazine-eluting stents prevented in-stent restenosis in a porcine model.
    Ma G; Ding S; Feng Y; Shen C; Chen L; Chen Z
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):201-5. PubMed ID: 17703137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic stent coatings: hirudin/iloprost combination.
    Alt E; Seliger C
    Semin Interv Cardiol; 1998; 3(3-4):177-83. PubMed ID: 10406690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The paclitaxel-eluting stent in percutaneous coronary intervention: part I: background and clinical comparison to bare metal stents.
    Gruchalla KJ; Nawarskas JJ
    Cardiol Rev; 2006; 14(2):88-98. PubMed ID: 16493246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.